22 results on '"Arora, Vipin"'
Search Results
2. Disruption of Spinal Noradrenergic Activation Delays Recovery of Acute Incision-Induced Hypersensitivity and Increases Spinal Glial Activation in the Rat
3. Adalimumab for the Treatment of Japanese Patients With Intestinal Behçet’s Disease
4. The divergence between core and headline inflation: Implications for consumers’ inflation expectations
5. Su1800 EFFICACY AND SAFETY OF MIRIKIZUMAB THERAPY IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 2 SHINE-1 STUDY
6. Sesamol Suppresses Neuro-Inflammatory Cascade in Experimental Model of Diabetic Neuropathy
7. Tu1712 EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES BASED ON PRIOR ADVANCED THERAPY FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
8. 781 PK, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY
9. 25665 Efficacy and safety of mirikizumab in psoriasis: 52-week results from the OASIS-1 randomized controlled trial
10. Capsaicin-induced depolymerization of axonal microtubules mediates analgesia for trigeminal neuropathic pain
11. 132 EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE
12. Tu1887 IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A PHASE 2 STUDY ANALYSIS USING THE SF-36 V2 STANDARD
13. Tu1888 EARLY AND SUSTAINED IMPROVEMENT IN STOOL FREQUENCY AND RECTAL BLEEDING FOLLOWING 52 WEEKS OF MIRIKIZUMAB TREATMENT
14. Tu1849 HISTOLOGIC REMISSION AND MUCOSAL HEALING IN A PHASE 2 STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
15. Su1967 DISEASE BURDEN AND PATIENT-REPORTED OUTCOME MEASURES AMONG ULCERATIVE COLITIS PATIENTS ACCORDING TO THERAPY AT ENROLLMENT INTO THE CORRONA IBD REGISTRY
16. Sa1817 REAL WORLD PREVALENCE OF BOWEL MOVEMENT URGENCY – A SNAPSHOT OF SYMPTOM EXPERIENCE REPORTED BY PATIENTS WITH ULCERATIVE COLITIS PARTICIPATING IN SPARC IBD
17. Sa1820 THE URGENCY NUMERIC RATING SCALE (NRS): A NOVEL PATIENT-REPORTED OUTCOME MEASURE TO ASSESS BOWEL URGENCY IN ADULT PATIENTS WITH ULCERATIVE COLITIS
18. P121 REAL WORLD PREVALENCE OF BOWEL MOVEMENT URGENCY – A SNAPSHOT OF SYMPTOM EXPERIENCE REPORTED BY PATIENTS WITH ULCERATIVE COLITIS PARTICIPATING IN SPARC IBD
19. P067 IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A PHASE 2 STUDY ANALYSIS USING THE SF-36 V2 STANDARD
20. P068 MIRIKIZUMAB TREATMENT IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
21. Tu1711 – Extended Treatment with Mirikizumab in Patients with Moderately-To-Severely Active Ulcerative Colitis: Results from a Phase 2 Trial
22. Neuroprotective effect of epigallocatechin-3-gallate against chronic alcohol induced cognitive deficits in rats: Possible role of oxidative stress and cytokine signaling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.